Published in J Natl Compr Canc Netw on February 01, 2006
Self-reported mammography use following BRCA1/2 genetic testing may be overestimated. Fam Cancer (2012) 0.87
Genetic counseling and testing for common hereditary breast cancer syndromes: a paper from the 2007 William Beaumont hospital symposium on molecular pathology. J Mol Diagn (2008) 0.86
Effect of pre-test genetic counseling for deaf adults on knowledge of genetic testing. J Genet Couns (2011) 0.85
Genetic risk assessment for women with epithelial ovarian cancer: referral patterns and outcomes in a university gynecologic oncology clinic. J Genet Couns (2013) 0.83
Detection of inherited mutations for hereditary cancer using target enrichment and next generation sequencing. Fam Cancer (2015) 0.82
Magnetic resonance characteristics of adult-onset Lhermitte-Duclos disease: An indicator for active cancer surveillance? Mol Clin Oncol (2014) 0.80
Contralateral risk-reducing mastectomy in young breast cancer patients with and without genetic cancer risk assessment. Ann Surg Oncol (2008) 0.80
Recent advances in breast cancer genetics. Cancer Treat Res (2008) 0.80
Breast cancer in a BRCA2 mutation carrier with a history of prostate cancer. Nat Rev Clin Oncol (2009) 0.78
Prophylactic oophorectomy rates in relation to a guideline update on referral to genetic counseling. Gynecol Oncol (2012) 0.76
Establishing a program for individuals at high risk for breast cancer. J Cancer (2013) 0.75
Use of BRCA Mutation Test in the U.S., 2004-2014. Am J Prev Med (2017) 0.75
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid (2009) 10.20
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 9.72
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 8.41
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2002) 7.84
Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med (2002) 6.94
Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell (2007) 6.52
Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med (2007) 6.47
BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer (2005) 5.57
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol (2005) 5.27
Breast-cancer risk in families with mutations in PALB2. N Engl J Med (2014) 4.97
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol (2010) 4.93
Implementing genomic medicine in the clinic: the future is here. Genet Med (2013) 4.89
Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol (2009) 4.84
Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A (2008) 4.76
Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet (2007) 4.69
Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA (2004) 4.52
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol (2008) 4.45
NCCN Clinical Practice Guidelines in Oncology: colon cancer. J Natl Compr Canc Netw (2009) 4.41
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol (2002) 4.38
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Prediction of germline mutations and cancer risk in the Lynch syndrome. JAMA (2006) 4.34
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA (2006) 4.09
The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol (2006) 3.96
Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol (2007) 3.94
Non-small cell lung cancer. J Natl Compr Canc Netw (2010) 3.93
Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet (2011) 3.91
Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas. Nat Genet (2002) 3.89
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Aggregate cost of mammography screening in the United States: comparison of current practice and advocated guidelines. Ann Intern Med (2014) 3.78
Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One (2012) 3.74
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol (2005) 3.44
Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res (2008) 3.41
NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw (2009) 3.37
Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. Radiology (2012) 3.36
Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res (2012) 3.33
MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Res (2006) 3.26
Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst (2002) 3.25
Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2009) 3.17
Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer. Science (2008) 3.16
Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol (2004) 3.10
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet (2009) 3.10
The UCSC Cancer Genomics Browser. Nat Methods (2009) 3.08
American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. J Clin Oncol (2014) 3.07
Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw (2013) 3.03
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol (2006) 3.02
The Scientific Foundation for personal genomics: recommendations from a National Institutes of Health-Centers for Disease Control and Prevention multidisciplinary workshop. Genet Med (2009) 2.91
Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol (2002) 2.80
Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. Nature (2010) 2.78
NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw (2009) 2.78
Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer (2009) 2.77
Validation of proposed DSM-5 criteria for autism spectrum disorder. J Am Acad Child Adolesc Psychiatry (2011) 2.72
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2005) 2.70
Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Clin Cancer Res (2006) 2.70
Agreement between self-reported breast cancer treatment and medical records in a population-based Breast Cancer Family Registry. J Clin Oncol (2005) 2.70
Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA (2005) 2.69
TGFBR1*6A and cancer risk: a meta-analysis of seven case-control studies. J Clin Oncol (2003) 2.68
A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations. Gynecol Oncol (2008) 2.65
Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet (2007) 2.64
Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2012) 2.62
Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA (2005) 2.59
A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am J Hum Genet (2010) 2.59
Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. Cancer Res (2010) 2.56
Influence of genetic discrimination perceptions and knowledge on cancer genetics referral practice among clinicians. Genet Med (2008) 2.53
Adoption of gene expression profile testing and association with use of chemotherapy among women with breast cancer. J Clin Oncol (2012) 2.53
Sharing BRCA1/2 test results with first-degree relatives: factors predicting who women tell. J Clin Oncol (2006) 2.53
Hereditary cancer predisposition syndromes. J Clin Oncol (2005) 2.49
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (2006) 2.49
Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO. J Natl Cancer Inst (2002) 2.45
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol (2012) 2.45
Genetic/familial high-risk assessment: breast and ovarian. J Natl Compr Canc Netw (2010) 2.45